EP
NAGE icon

Essential Partners’s Niagen Bioscience NAGE Stock Holding History

Essential Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$456 Sell
156
-71
-31% -$227 ﹤0.01% 2424
2026
Q2 		$724 Sell
227
-1,157
-84% -$4.7K ﹤0.01% 2373
2026
Q1 		$6.1K Sell
1,384
-2,461
-64% -$13.3K ﹤0.01% 1486
2025
Q4 		$24.5K Sell
3,845
-874
-19% -$6.08K 0.01% 834
2025
Q3 		$44K Buy
4,719
+467
+11% +$4.71K 0.01% 629
2025
Q2 		$61.3K Buy
+4,252
New +$42K 0.02% 429

Other funds holding NAGE

SteelPeak Wealth
SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $211M AUM 58.81% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
ANBT
American National Bank & Trust Wichita Falls, Texas $1.09B AUM 26.59% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
JTBR
James T. Borello RIA East Dundee, Illinois $482M AUM 14.29% 1-Year Est. Return

Essential Partners's NAGE Position: Q3 2026 in Review

Essential Partners reduced its Niagen Bioscience (NAGE) stake by 31% in Q3 2026, selling an estimated $227 and leaving 156 shares worth $456. The position accounts for ﹤0.01% of the portfolio, ranked #2424.

Essential Partners first reported a position in NAGE in Q2 2025 and has held it in 6 quarters since. The position peaked at $61.3K in Q2 2025. 9 funds tracked by Wall St. Rank hold NAGE as of Q3 2026.

  • Essential Partners held 156 shares of Niagen Bioscience worth $456 as of Q3 2026.
  • Essential Partners sold 71 Niagen Bioscience shares in Q3 2026, an estimated $227.
  • Niagen Bioscience made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2424 holding.
  • Essential Partners first reported a position in Niagen Bioscience in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Niagen Bioscience position peaked at $61.3K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.